Abstract
On this work we report that despite of a decline in the total anti-Spike antibodies the neutralizing antibodies remains at a similar level for an average of 98 days in a longitudinal cohort of 59 Hispanic/Latino exposed to SARS-CoV-2. We are also reporting that the percentage of neutralization correlates with the IgG titers and that in the first collected samples, IgG1 was the predominant isotype (62.71%), followed by IgG4 (15.25%), IgG3 (13.56%), and IgG2 (8.47%) during the tested period. The IgA was detectable in 28.81% of subjects. Only 62.71% of all subjects have detectable IgM in the first sample despite of confirmed infection by a molecular method. Our data suggests that 100% that seroconvert make detectable neutralizing antibody responses measured by a surrogate viral neutralization test. We also found that the IgG titers and neutralizing activity were higher after the first dose in 10 vaccinated subjects out of the 59 with prior infection compare to a subgroup of 21 subjects naïve to SARS-CoV-2. One dose was enough but two were necessary to reach the maximum percentage of neutralization in subjects with previous natural infection or naïve to SARS-CoV-2 respectively. Like the pattern seen after the natural infection, after the second vaccine dose, the total anti-S antibodies and titers declined but not the neutralizing activity which remains at same levels for more than 80 days after the first vaccine dose. That decline, however, was significantly lower in pre-exposed individuals which denotes the contribution of the natural infection priming a more robust immune response to the vaccine. Also, our data indicates that the natural infection induces a more robust humoral immune response than the first vaccine dose in unexposed subjects. However, the difference was significant only when the neutralization was measured but not by assessing the total anti-S antibodies or the IgG titers. This work is an important contribution to understand the natural immune response to the novel coronavirus in a population severely hit by the virus. Also provide an invaluable data by comparing the dynamic of the immune response after the natural infection vs. the vaccination and suggesting that a functional test is a better marker than the presence or not of antibodies. On this context our results are also highly relevant to consider standardizing methods that in addition to serve as a tool to follow up the immune response to the vaccines may also provide a correlate of protection.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The Puerto Rico Science, Technology and Research Trust supported research reported in this work under agreement number 2020-00272 to AME and CAS. Also, the University of Puerto Rico contribute with the UPR-COVID-19 Grant to CAS and AME. This work was also supported by 1U01CA260541-01 to CAS (NCI/NIAID). This work was also partially funded by Saint Louis University COVID-19 research Seed Funding to awarded to AKP and awarded to JDB.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All volunteers (< 21 years old) are participating in the IRB approved clinical protocol Molecular Basis and Epidemiology of Viral infections circulating in Puerto Rico, Pro0004333. Protocol was submitted to, and ethical approval was given by Advarra IRB on April 21, 2020. An Informed Consent Form and a study questionnaire also approved by the IRB were administered to the volunteers. Plasma donors were self-enrolled and were amply verbally informed about the relevance of their participation as plasma donors for the treatment of COVID-19 patients. They were also given the opportunity to ask questions. Furthermore, they were handled throughout the standard blood donors protocols signing the Blood Banks standard consent with ample information about the use of their samples for research purposes only. In addition, before receiving the samples from these sources the subjects data that has been stripped of all identifiers so that the information cannot be traced back to an individual.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All additional data collected during this study is available as supplementary information
